MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN CANCER.

Publication Type:

Journal Article

Source:

Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 20, Issue 12, p.3280-8 (2014)

Keywords:

2014, Center-Authored Paper, Experimental Histopathology Core Facility, Human Biology Division, May 2014

Abstract:

Residual disease (RD) following primary cytoreduction is associated with adverse overall survival in patients with epithelial ovarian cancer. Accurate identification of patients at high risk of RD has been elusive, lacking external validity and prompting many to undergo unnecessary surgical exploration. Our goal was to identify and validate molecular markers associated with high rates of residual disease. Methods: We interrogated two publicly available datasets from chemonaïve primary high-grade serous ovarian tumors for genes overexpressed in patients with RD and significant at a 10% false discovery rate (FDR) in both datasets. We selected genes with wide dynamic range for validation in an independent cohort using qRT-PCR to assay gene expression, followed by blinded prediction of a patient subset at high risk for RD. Predictive success was evaluated using a one-sided Fisher's exact test.